Research at the Clayton Foundation has led to several FDA approved drugs, medical devices and diagnostic assays along with the following pipeline in development by our licensees.
Clinical Pipeline
eli-cel (Lenti-D)
Indication: Cerebral ALD
Phase II / III - accelerated assessment of MAA
beti-cel (LentiGlobin)
Indication: Beta Thalassemia
Phase III
LentiGlobin
Indication: Sickle Cell Disease
Phase II / III
PEC-Encap VC-01
Indication: All T1 Diabetes
Phase I / II
PEC-Direct VC-02
Indication: High-risk T1 Diabetes
Phase I / II
PEC-QT
Indication:All T1 and T2 Diabetes
Preclinical
Oral Vimo-001
Indication: Solid Tumors
Phase I
Pre-Clinical Pipeline
RT-200
Indication: Type II Diabetes
Advanced Preclinical
RT-300
Indication: Congestive Heart Failure
Preclinical
RT-400
Indication: Acute decompensated heart failure
Preclinical
GrB-Fc-SD1
Indication: Mesotheliomas & Pancreatic Cancers
Preclinical
Grb-Fc-IT4
Indication: Breast, Lung, Melanoma Cancers
Preclinical
Grb-Fc-4D5
Indication: Breast, GEJ Ca Cancers
Preclinical
Grb-Fc-HMEL
Indication: Melanoma, Breast Cancers
Preclinical
Early Stage Pipeline
JamC mAb
Indication: B Cell Lymphomas
Animal in vivo POC
Olfml3 mAb
Indication: Metastatic breast cancer
Animal in vivo POC
SrpX2 mAb
Indication: TBD
Animal in vivo POC
SmartLaser Wire and SmartKnife
Applications: Chronic Total Occlusions (CTOs) and Brain tumors
Prototype development
R1-MMAE
Indication: Ovarian cancer
Animal in vivo POC